icon

Armed with a high profile licensing deal involving Pfizer (PFE), Lpath, Inc. (LPTN.OB) and its share price were gaining momentum late last year and into the early stages of 2012 before a temporary halt in the company's iSONEP trial was announced in January, an event that sent shares back to the sub-one dollar mark.

Read more

Already a swift mover and big winner for investors this year, Immunocellular Therapeutics (IMUC.OB) may still have enough short to mid term catalysts on the horizon to propel shares even higher. A financing deal announced early in the year restocked the company's war chest with cash and exposed the fact that institutional interest in the company is growing, just as the Phase II glioblastoma trial for ICT-107 progresses on schedule.

Read more

The recent run of Immunocellular Therapeutics (IMUC.OB) nearly reached the two dollar mark on a few occasions last week, and eyes will be on the stock this week to see if that barrier can again be taken down.

IMUC has just about doubled in a short period time and the quick rise was fueled by new institutional interest as well as attention being put on the company's pipeline, led by ICT-107, an immunotherapeutic treatment for glioblastoma...

Read more

Manhattan Pharmaceuticals (TGTX.OB) was making some noise last year at around this time, and it looks like the company is ready to roll again, now armed with a new ticker symbol (previously MHAN.OB) and a fresh licensing agreement.

The company had been dead for the better part of last year, aside from some short term moves, but last week its stock registered a 600% gain one day and also showed some life on Friday with a 15% pop...

Read more

Capstone Turbine (CPST) announced earnings for the company's fiscal third quarter last week, and although the company took another solid step forward on the path towards profitability, the general consensus on the street, according to numerous headlines from various sources, is that Capstone's report was an earnings "miss."

Read more

On the heels of an earnings report that had Pharmacyclics, Inc. (PCYC) raking in nearly sixty million dollars during the company's fiscal second quarter - a quarter that ended with over $240 million in the PCYC bank account - shares spiked pretty significantly, surging by nearly twenty percent on Friday to close the day at the $23.23 mark. That's a monumental number for a stock that traded for just around a buck four years ago...

Read more

InVivo Therapeutics (NVIV.OB) is moving again.

Shares flew to nearly three dollars late last year, from well under the dollar mark as news circulated regarding the company's revolutionary treatment for treating and potentially curing the devastating effects of spinal cord injuries (SCI) and paralysis, but have since dropped back towards two dollars as the traders went looking for the next immediate-term payday.

That said, NVIV could be positioned for another move higher with multiple catalysts pending - including the initiation of human trials - and might also be shaping up to be quite the buyout candidate...

Read more

At the conclusion of each week, VFC's Stock House examines the stocks and stories that made news through various sectors during the previous trading week, but may also make headlines or influence trends during the upcoming week as well.

A modest pullback on Friday capped off a solid run that had been fueled by encouraging jobs data, but some still argue that the new job growth is not enough to justify a general turnaround in economic indicators. Global tensions are also still in full swing, with the threat of an Israeli strike on Iran being openly discussed, along with talk of a total meltdown in Syria.

That's on top of continued turmoil in Europe, with Greece again dominating the international economic headlines as the country faces mass cuts or default. The turmoil led to a few high-profile resignations over the weekend.

All in all, it should be another exciting - and possibly volatile - week for the traders. With all the excitement, keep an eye on some of these stocks...

Read more

With Super Bowl week nearing an end, here's a few stocks that have looked as sweet as a Manning to Manningham pass lately...

GelTech Solutions (GLTC): Trading volume and share price have been on the move for GelTech Solutions (GLTC.OB) for a few weeks now, and after a brief period of consolidation at around the one dollar mark, GLTC has continued to trade at nearly ten times the daily average with a continued push higher...

Read more

At the conclusion of each week, VFC's Stock House examines the stocks and stories that made news through various sectors during previous trading week, but may also make headlines or influence trends during the upcoming week as well.

This week could be a good one, in just about all sectors, given the positive economic indicators released last week that had the markets hitting highs not seen in years. Although the big news that everyone is talking about is the Facebook IPO, there's going to be some other stocks and stories to watch once the hangovers wear off from the Super Bowl.

Here's just a few of those stories to watch...

Read more

Although trading in much different sectors, shares of Capstone Turbine (CPST) have had a similar trading pattern as Titan Pharmaceuticals (TTNP.OB) - another company long followed by VFC's Stock House - over the past couple of years, and just on the heels of TTNP's most recent price run, shares of CPST are again starting to roll...

Read more

One of this week's hot movers, GelTech Solutions (GLTC.OB), bursted through a dollar on Thursday afternoon, supported by trading volume that was more than ten times the normal average. Volume had been increasing over the past week on anticipation that distribution for FireIce, GelTech's flagship product that could quickly revolutionize the firefighting industry, would quickly boom now that governments around the globe have started taking notice of the potential revenue and resource savings that FireIce could provide...

Read more

IMUC: A recent financing deal brought shares of Immunocellular Therapeutics (IMUC.OB) crashing down towards a dollar earlier this year, but encouraging pipeline news, high volume and new institutional interest has quickly revived the share price and the stock closed Wednesday seventy percent higher than is January lows.

A surge in the Dendreon (DNDN) share price has led to a sector-wide rebound, thanks to...

Read more

MNKD: Mannkind Corporation (MNKD) looked to be on a rebound as shares surpassed the three dollar mark recently and some media outlets began predicting a short squeeze, give the huge short interest in the stock over the past months.

Heavy insider ownership also added intrigue to the Mannkind story, which could quickly regain traction once it starts to look as if the latest round of trials requested by the FDA for Afrezza approval will be enough to justify an FDA approval...

Read more